Inhibrx Biosciences, Inc.

INBX Nasdaq SEC CIK 2007919
Follow Inhibrx Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $2M
Net income −$38.7M −9.9% vs same quarter last year
EPS, diluted −$2.46 −7.9% vs same quarter last year
Operating cash flow −$34.6M −2.3% vs same quarter last year
Revenue by quarter
$100K
$0
$1.3M
$0
$0
$0
$2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
  • Revenue
  • Net income
−$500M$0$500M$1B$1.5B$2BFY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$1.3M−$140.1M
FY24$200K$1.7B
FY23$1.8M−$241.4M
FY22--
MarginsShare of revenue
  • Operating margin
  • Net margin
−500000%0%500000%1000000%FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−10386.5%−10773.5%
FY24−165724%843786%
FY23−12178.9%−13408.9%
FY22--
Free cash flowOperating cash flow minus capital expenditure
−$200M−$150M−$100M−$50M$0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$129.8M
FY24−$197M
FY23−$197.9M
FY22-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Inhibrx Biosciences
  • Healthcare median
−250000%0%250000%500000%750000%1000000%FY22FY23FY24FY25
Show the numbers
YearInhibrx BiosciencesHealthcare median
FY25−10773.5%−30.6%
FY24843786%−47%
FY23−13408.9%−58%
FY22-−80.4%